Korro Bio is trading at $13.80 (-5.19%) as it extends its post-trial volatility with no new company-specific catalysts identified in current coverage.
- The stock remains under pressure following the failed KRRO-110 program and the paused Novo Nordisk RNA partnership.
- Broader biotech weakness is weighing on shares, with the XBI down 2.69% as investors rotate away from high-beta names amid a wider risk-off market tone.